Test Code AGA Alpha-Galactosidase, Leukocytes
Reporting NameAlpha-Galactosidase, Leukocytes
Performing LaboratoryMayo Medical Laboratories in Rochester
The following algorithms are available in Special Instructions:
-Fabry Disease: Newborn Screen-Positive Follow-up
-Fabry Disease Testing Algorithm
Specimen TypeWhole Blood ACD
Specimen must arrive within 72 hours of draw to be stabilized. Specimen received after 72 hours could have falsely normal results. Draw specimen Monday through Thursday only and not the day before a holiday. Specimen should be drawn and packaged as close to shipping time as possible.
Preferred: Yellow top (ACD solution B)
Acceptable: Yellow top (ACD solution A)
Specimen Volume: 7 mL
Collection Instructions: Do not transfer blood to other containers.
1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.
2. If not ordering electronically, submit a Biochemical Genetics Request Form (Supply T439) with the specimen.
Specimen Minimum Volume
Specimen Stability Information
|Whole Blood ACD||Refrigerated (preferred)||72 hours|
Reject Due To
Mild OK; Gross reject
≥23.1 nmol/hour/mg protein
An interpretative report will be provided.
Note: Results from this assay do not reflect carrier status because of individual variation of alpha-galactosidase enzyme levels.
Day(s) and Time(s) Performed
Specimens are processed Monday through Sunday. Assay is performed on Wednesday.
Analytic Time8 days
Specimen Retention TimeWBC homogenate stored 1 month
Diagnosis of Fabry disease in males
Verifying abnormal serum alpha-galactosidase results in males with a clinical presentation suggestive of Fabry disease
Deficiency of alpha-galactosidase A (alpha-Gal A) is diagnostic for Fabry disease in males.
Urine sediment analysis (CTSA / Ceramide Trihexoside/Sulfatide Accumulation in Urine Sediment, Urine) for the accumulating trihexoside substrate is also recommended.
Carriers usually have alpha-galactosidase levels in the normal range and molecular sequence analysis of the GLA gene is recommended (FABMS / Fabry Disease, Full Gene Analysis).
Test ClassificationThis test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information
LOINC Code Information
|Result ID||Reporting Name||LOINC Code|
|32302||Reason for Referral||42349-1|